| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.70(B) |
| Last
Volume: |
5,124,230 |
Avg
Vol: |
4,159,145 |
| 52
Week Range: |
$6.18 - $11.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1115 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
183,601 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,048,338 |
| Total People Bought |
0 |
0 |
0 |
10 |
| Total Buy Transactions |
0 |
0 |
0 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
11,387 |
| Total Sell Value |
$0 |
$0 |
$0 |
$69,059 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mckee Amy E |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
40,331 |
|
- |
|
| Levin Alan G |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
64,271 |
|
- |
|
| Galson Steven K |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
24,991 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
99,138 |
|
- |
|
| Sanders Machelle |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
40,242 |
|
- |
|
| Milano Vincent |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
89,760 |
|
- |
|
| Frank Steven |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
14,699 |
|
- |
|
| Heggie Theresa |
Director |
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
65,352 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2025-05-30 |
4 |
A |
$10.75 |
$5,622 |
D/D |
523 |
77,260 |
|
- |
|
| Frank Steven |
Director |
• • – |
2025-05-30 |
4 |
A |
$10.75 |
$3,580 |
D/D |
333 |
2,199 |
|
- |
|
| Frank Steven |
Director |
• • – |
2025-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,866 |
1,866 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2025-03-31 |
4 |
D |
$7.50 |
$56,438 |
D/D |
(7,525) |
377,318 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2025-02-28 |
4 |
A |
$8.61 |
$5,622 |
D/D |
653 |
76,737 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-12-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
30,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-12-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
1,429,109 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2024-12-19 |
4 |
D |
$7.39 |
$45,049 |
D/D |
(6,096) |
384,843 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
125,950 |
390,939 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-12-19 |
4 |
D |
$7.39 |
$103,534 |
D/D |
(14,010) |
1,449,109 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
362,100 |
1,463,119 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2024-12-19 |
4 |
D |
$7.39 |
$18,187 |
D/D |
(2,461) |
423,546 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
125,950 |
426,007 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2024-12-19 |
4 |
D |
$7.39 |
$18,187 |
D/D |
(2,461) |
412,729 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
120,700 |
415,190 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2024-12-19 |
4 |
D |
$7.39 |
$18,187 |
D/D |
(2,461) |
377,867 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2024-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
120,700 |
380,328 |
|
- |
|
465 Records found
|
|
Page 1 of 19 |
|
|
0.40 (4.27%) 
